Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 9, 2004 - Issue 2
Submit an article Journal homepage
94
Views
13
CrossRef citations to date
0
Altmetric
Review

New drugs for the treatment of attention-deficit/hyperactivity disorder

Caroly S Pataki UCLA Neuropsychiatric Institute, Room 27-370C, 760 Westwood Plaza, Los Angeles, CA 90024, USA
,
David T Feinberg 300 UCLA Medical Plaza, Suite 1235, Los Angeles, CA 90095, USA
&
James J McGough 300 UCLA Medical Plaza, Suite 1414, Los Angeles, CA 90095, USA. [email protected]
Pages 293-302 | Published online: 24 Feb 2005

Bibliography

  • SZATMARI P, OFFORD DR,BOYLE MH: Ontario child health study: prevalence of attention deficit disorder with hyperactivity. I Child Psycho]. Psychiatry (1989) 30:219–230.
  • KANBAYASHI Y, NAKATA Y, FUJII K, KITA M, WADA K: ADHD-related behavior among non-referred children: parents' ratings of DSM-III-R symptoms. Child Psychiatry Hum. Dev (1994) 25:13–29.
  • BAUMGAERTAL A, WOLRAICH M, DIETRECH M: Comparison of diagnostic criteria for attention deficit hyperactivity disorder in a German elementary schoolsample. I Am. Acad. Child Adolesc. Psychiatry(1995) 34: 629–638.
  • JENSEN PS, WATANABE HK, RICHTERS JE, CORTES R, ROPER M, LIU S: Prevalence of mental disorder in military children and adolescents: findings from a two-stage community survey. J. Am. Acad. Child Adolesc. Psychiatry(1995) 34:1514–1524.
  • WOLRAICH ML, HANNAH JN, PINNOCK TY, BAUMGAERTAL A, BROWN J: Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J. Am. Acad. Child Adolesc. Psychiatry(1996) 35:319–324.
  • SZATMARI P: The epidemiology of attention-deficit hyperactivity disorders. In Child and Adolescent Psychiatry Clinics ofNorth America: Attention deficit disorder G Weiss (Ed.), Saunders, Philadelphia (1992).
  • LAUFER MW, DENHOFF E: Hyperkinetic behavior syndrome in children. Pediatr. (1957) 50:463–474.
  • WILENS TE, BIEDERMAN J, SPENCER TJ: Attention deficit/ hyperactivity disorder across the lifespan. Anna. Rev Med. (2002) 53:113–131.
  • •Excellent review article of ADHD phenomenology and treatment.
  • MURPHY K, BARKLEY RA: Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Comp. Psychiatry (1996) 37:393–401.
  • MURPHY K, BARKLEY RA: Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers; implications for clinical diagnosis. J. Att. Disorders (1996) 1:147–161.
  • BARKLEY RA, FISCHER M, SMALLISH L, FLETCHER K: The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. Abnorm. Psychol (2002) 111:279–289.
  • •Longitudinal ADHD follow-up study demonstrating rate of persistence into young adulthood.
  • KESSLER RC: Prevalence of adult ADHD in the United States; results from the national comorbidity survey replication. Proceedings of the 157-h Annual Meeting of the American Psychiatric Association. New York (2004).
  • BARKLEY RA: Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J. Clin. Psychiatry (2002) 63 (Suppl. 12):10–15.
  • ROBISON LM, SCLAR DA, GALIN RS: National trends in the prevalence of attention - deficit disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clin. Pediatr (1999) 38:209–217.
  • CHAN E, ZHAN C, HOMER CJ: Health care use and costs for children with attention deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey. Arch. Pediatr. Adolesc. Med. (2002) 156:504–511.
  • BIEDERMAN J, WILENS TE, MICK E, FARAONE SV, SPENCER T: Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol. Psychiatry (1998) 44: 269–273.
  • WILENS TE, BIEDERMAN J, MICK E: Does ADHD effect the course of substance abuse? Findings from a sample of adults with and without ADHD. Am. J. Addict. (1998) 7:156–163.
  • POMERLEAU CS, DOWNEY KK, SNEDECKOR SM, MEHRINGER AM, MARKS JL, POMERLEAU OF: Smoking patterns and abstinence effects in smokers with no ADHD, childhood ADHD, and adult ADHD symptomatology. Addict. Behav (2003) 28:1149–1157.
  • BIEDERMAN J, FARAONE SV, SPENCER T et al.: Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficithyperactivity disorder. Am. J. Psychiatry(1993) 150:1792–1798.
  • MANNUZZA S, KLEIN RG, BESSLER A,MALLOY P, LAPADULA M: Adult outcome of hyperactive boys. Am. J. Psychiatry (1993) 50:565–576.
  • AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition-Text Revision (DSM-IV-TR). Washington, D.C., American Psychiatric Association (2000).
  • FARAONE SV, DOYLE AE: The nature and heritability of attention-deficit/ hyperactivity disorder. Child Adolesc. Psychiatr. Clin. N Am. (2001) 10:299–316.
  • ARCOS-BURGOS M, CASTELLANOS FX, KONECKI D et al.: Pedigree disequilibrium test (PDT) replicates association and linkage between DRD4 and ADHD in multigenerational and extended pedigrees from a genetic isolate. Ma Psychiatry (2004) 9:252–259.
  • BAKKER SC, VAN DER MEULEN EM, BUITELAAR JK et al.: A whole-genome scan in 164 Dutch sib pairs with attention-deficit/hyperactivity disorder; suggestive evidence for linkage on chromosomes 7p and 15q. Am. J. Hum. Genet. (2003) 72:1251–1260.
  • FISCHER SE, FRANKS C, MCCRACKEN JT et al: A genome-wide scan for loci involved in attention-deficit/ hyperactivity disorder (ADHD). Am. J. Hum. Genet. (2002) 70:1183–1196.
  • •First ADHD genome scan.
  • COOK EH, STEIN MA,KRASOWSKI MD et al.: Association of attention deficit disorder and the dopamine transporter gene. Am. J. Hum. Genet. (1995) 56:993–998.
  • FARAONE SV, DOYLE AE, MICK E, BIEDERMAN J: Meta-analysis of the association between the 7-repeat allele of the dopamine d(4) receptor gene and attention deficit hyperactivity disorder.Am. J. Psychiatry (2001) 158: 104–113.
  • MAHER BS, MARAZITA ML, FERRELL RE, VANYUKOV MM: Dopamine system genes and attention deficit hyperactivity disorder; a meta-analysis. Psychiatc Genet. (2002) 12:207–215.
  • SMALLEY SL: Genetic influences in childhood-onset psychiatric disorders: autism and attention-deficit/hyperactivitydisorder. Am. J. Hum. Genet. (1997) 60:1276–1282.
  • MICK E, BIEDERMAN J, FARAONE SV,SAYER J, KLEINMAN NS: Case-control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol us, and drug use during pregnancy. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41:378–385.
  • MILBERGER S, BIEDERMAN J, FARAONE SV, CHEN L, JONES J: Is maternal smoking a risk factor for attention deficit hyperactivity disorder in children. Am. J. Psychiatry(1996) 153: 1138–1142.
  • KOTIMAA AJ, MIOLANEN I, TAANILA A et al.: Maternal smoking and hyperactivity in 8-year old children. Am. Acad. Child Adolesc. Psychiatry (2003) 42:826–833.
  • TUTHILL RW: Hair lead levels related to children's classroom attention-deficit behavior. Arch. Environ. Health (1996) 51:363–383.
  • LEIBSON CL, KATUSIC SK, BARBARESI WJ, RANSOM J, O'BRIEN PC: Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA (2001) 285:60–66.
  • GUEVARA J, LOZANO P, WICKIZER T,MELL L, GEPHART H: Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics (2001) 108:71–78.
  • SZATMARI P, OFFORD DR, BOYLE MH: Correlates, associated impairments and patterns of service utilization of children with attention deficit disorder. J. Child Psycho]. Psychiatry (1989) 30:205–217.
  • BARKLEY RA, MURPHY KR, KWASNIK D: Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics (1996) 98:1089–1095.
  • BARKLEY RA, FISCHER M, SMALLISH L, FLETCHER K: Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics (2003) 112:1459–1460.
  • •Longitudinal study showing no increased risk of substance abuse in children treated with stimulants.
  • WILENS TE, FARAONE SV, BIEDERMAN J, GUNAWARDENE S: Does stimulant therapy of attention-deficit/ hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics (2003) 111:179-185.
  • GREENHILL LL, HALPERIN JM, ABIKOFF H: Stimulant medications. I Am. Acad. Child Adolesc. Psychiatry (1999) 38:503–512.
  • SAYLOR KE, BUERMEYER CM, SPENCER TJ, BARKLEY RA: Adaptive changes related to medication treatment of ADHD: listening to parents of children in clinical trials of a novel nonstimulant medication." Clin. Psychiatry (2002) 63\(Suppl. 12):23–28.
  • SPENCER T, BIEDERMAN J,WILENS T et al.: Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J. Am. Acad. Child Adolesc. Psychiatry (1996) 35:409–432.
  • ELIA J, BORDCHERDING B, RAPOPORT J, KEYS OR C: Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res. (1991) 36:141–155.
  • BARKLEY RA, MCMURRAY MG, EDELBROCK CS et al.: Side effects of methylphenidate in children with attention deficit hyperactivity disorder; a systematic, placebo-controlled evaluation. Pediatrics (1990) 86:184–192.
  • BIEDERMAN J, LOPEZ FA,BOELLNER SW, CHANDLER MC: A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics (2002) 110:258–266.
  • MCGOUGH JJ, BIEDERMAN J, GREENHILL L et al.: Plasma amphetamine concentration and adverse events in ADHD treatment. Proceedings of the 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry Honolulu, HI (2001).
  • WILENS T, PELHAM W, STEIN M et al.: ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study.I Am. Acad. Child Adolesc. Psychiatry (2003) 42:424–433.
  • MCGOUGH JJ, BIEDERMAN J, WIGAL S et al: Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. I Am. Acad. Child Adolesc. Psychiatry (In press).
  • SWANSON JM, KRAEMER HC, HINSHAW SP et al.: Clinical relevance of the primary findings of the MTA; success rates based on severity of ADHD and ODD symptoms at the end of treatment. J. Am. Acad. Child Adolesc. Psychiatry (2001) 40:168–179.
  • ROWLAND AS, SKIPPER B,RABINER D et al: The effectiveness of ADHD medication treatment in an epidemiologic sample. Proceedings of the 5a-h Annual Meeting of the American Academy of Child and Adolescent PsychiatryMiami, FL (2003).
  • CHARACH A, ICKOWICZ A,SCHACHAR R: Stimulant treatment over five years: adherence, effectiveness, and adverse events. J. Am. Acad. Child Adolesc. Psychiatry(2004) 43: 559–567.
  • •Illustrates problems of adherence with currently available ADHD medications.
  • MICHELSON D, ALLEN AJ, BUSNER J et al : Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am. I Psychiatry (2002) 159: 1896–1901.
  • MICHELSON D, BUITELAAR JK, DANCKAERTS M et al: Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. I Am. Acad. Child Adolesc. Psychiatry (2004) 43:896–904.
  • MICHELSON D, ADLER L,SPENCER T et al: Atomoxetine in adults with ADHD; two randomized, placebo-controlled studies. Biol. Psychiatry (2003) 15:112–120.
  • WERNICKE JF, KRATOCHVIL CJ: Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. I Clin. Psychiatry (2002) 63\(Suppl. 12):50–55.
  • WERNICKE JF, ADLER L, SPENCER T et al: Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J. Clin. Psychopharmacol (2004) 24:30–35.
  • KEMNER J, STARR L, CICCONE PE,LYNCH J: OROS MPH provides greater ADHD improvement than atomoxetine. Proceedings of the 157' Meeting of the American Psychiatric Association.New York (2004).
  • WIGAL S, MCGOUGH J, POSENR K et al: Analog classroom study of amphetamine extended release and atomoxetine in youth with ADHD. Proceedings of the 157-h Meeting of the American Psychiatric Association. New York (2004).
  • WILENS TE, SPENCER TJ,BIEDERMAN J et al: A controlled clinical trial of buproprion for attention-deficit/ hyperactivity disorder in adults. Am. J. Psychiatry (2001) 158: 282–288.
  • BARRICKMAN LL, PERRY PJ, ALLEN AJ et al.: Buproprion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder.I Am. Acad. Child Adolesc. Psychiatry (1995) 34:649–657.
  • SWANSON J, BIEDERMAN J, BOELLNER SW, EARL C, LOPEZ FA: Modafinil as therapy for ADHD in children: an 8-week, open-label study. Scientific Proceedings of the Proceedings of the 44th Annual Meeting. NCDEU, Phoenix (2004).
  • HEDGES D, REIMHERR FW,ROGERS A, STRON R, WENDER PH: An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol Bull. (1995) 31:779–783.
  • FINDLING RL, SCHWARTZ MA, FLANNERY DJ, MANOS MJ: Venlafaxine in adults with attention-deficit/ hyperactivity disorder. I Am. Acad. Child Adolesc. Psychiatry (1999) 38:1551–1559.
  • WILENS TE, BIEDERMAN J, PRINCE J et al: Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am.Psychiatry (1996) 153: 1147–1153.
  • SPENCER T, BIEDERMAN J,COFFEY B: A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry (2002) 59:649–656.
  • PATAKI CS, CARLSON GA, KELLY KL et al: Side effects of methylphenidate and desipramine alone and in combination in children. I Am. Acad. Child Adolesc. Psychiatry (1993) 32: 1065–1072.
  • JENSEN P, KETTLE L, ROPER MT et al: Are stimulants overprescribed? Treatment of ADHD in four U.S. communities. Am. Acad. Child Adolesc. Psychiatry (1999) 38:269–270.
  • •Epidemiological study demonstrating that rates of ADHD treatment are less than the estimated prevalence of the disorder.
  • SPENCER TJ, BIEDERMAN J, WILENS TE, FARAONE SV: Overview and neurobiology of attention-deficit/ hyperactivity disorder. I Clin. Psychiatry (2002) 63\(Suppl. 12):3–9.
  • PLISZKA SR, MCCRACKEN JT, MAAS JW: Catecholamines in attention-deficit hyperactivity disorder. Am. Acad. Child Adolesc. Psychiatry (2002) 35:264–272.
  • SOLANTO MV: Dopamine dysfunction inAD/HD: integrating clinical and basic neuroscience research. Behav. Brain Res. (2002) 130:65–71.
  • DOUGHERTY DD, BONAB AA, SPENCER TJ et al.: Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet (1999) 354:2132–2133.
  • KRAUSE KH, DRESEL SH, DRASUSE J, KUNG HF, TATSCH K: Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. NeuroscL Lett. (2000) 285:107–110.
  • WINSBURG BG, COMINGS DE: Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. I Am. Acad. Child Adolesc. Psychiatry (1999) 38:1474–1477.
  • ROMAN T, SZOBOT C, MARTINE S, BIEDERMAN J, ROHDE LA, HUTZ MH: Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics (2002) 12:497–499.
  • KIRLEY A, LOWE N, HAWI A et at. Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am. I Med. Genetics (2003) 121:B50–B54.
  • STEIN MA, WALDMAN ID, SARAMPOTE C, SEYMOUR K, COOK EH: Dopamine transporter genotype (DAT1) predicts stimulant response in children with attention deficit hyperactivity disorder. Pediatric Res. (2004) (In Press).
  • SWANSON JM, WIGAL SB, WIGAL T et al.: A comparison of once-daily extended release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics (2004) 113:E206–E216.
  • PLISZKA SR, BROWNE RG,OLVERA RL, WYNNE SK: A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment ofattention-deficit/hyperactivity disorder. Am. Acad. Child Adolesc. Psychiatry(2000) 39:619–626.
  • AUILER JF, LIU K, LYNCH JM, GELOTTE CK: Effects of food on early drug exposure from extended-release stimulants; results from the Concerta, Adderall XR Food Evaluation (CAFE) Study. Carr. Med. Res. Opin. (2002) 18:311–316.

Website

  • http://www.iddb3.com The Investigational Drugs Database © 1997–2004 Derwent Information Ltd.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.